{
  "main_header": {
    "sid": 10039782,
    "name": "Aptus Pharma",
    "stock_name": "Aptus Pharma",
    "full_name": "Aptus Pharma Ltd",
    "name_url": "stocks-analysis/aptus-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "262.00",
    "chg": -5.3,
    "chgp": "-1.98%",
    "dir": -1,
    "prev_price": "267.30",
    "mcapval": "183.00 Cr",
    "mcap": "",
    "scripcode": 544529,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE15XJ01010",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": 4000,
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/aptus-pharma-10039782-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [],
    "total": 0,
    "sid": "10039782",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/aptus-pharma-10039782"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "10-Jan-2026",
      "details": "Compliance Certificate under Regulation 74 (5) of SEBI (DP) Regulations 2018",
      "source": "BSE"
    },
    {
      "caption": "Regulation 30 Disclosure - Entry Into The Urology Therapy Segment",
      "datetime": "21-Nov-2025",
      "details": "Regulation 30 Disclosure - Entry into the Urology Therapy Segment",
      "source": "BSE"
    },
    {
      "caption": "Intimation Of New Product- ENZYKING SYRUP",
      "datetime": "12-Nov-2025",
      "details": "Intimation of new product- ENZYKING SYRUP",
      "source": "BSE"
    }
  ],
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

No Recent News for the Company

View All News